Statements (42)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
carbonic anhydrase inhibitor |
| gptkbp:approvalYear |
1998
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
S01EC04
|
| gptkbp:brand |
Azopt
|
| gptkbp:CASNumber |
138890-62-7
|
| gptkbp:chemicalFormula |
C12H21N3O5S3
|
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to sulfonamides |
| gptkbp:developedBy |
gptkb:Alcon
|
| gptkbp:drugClass |
ophthalmic antiglaucoma agent
|
| gptkbp:eliminationHalfLife |
111 days
|
| gptkbp:excretion |
renal
|
| gptkbp:hasInChIKey |
QFFGVLORLPOAEC-RUZDIDTESA-N
|
| gptkbp:hasSMILES |
CCNC1=NC2=C(S1(=O)=O)SC(=C2)S(=O)(=O)NCCCOC
|
| https://www.w3.org/2000/01/rdf-schema#label |
brinzolamide
|
| gptkbp:IUPACName |
(R)-4-Ethylamino-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
|
| gptkbp:KEGGID |
D07613
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits carbonic anhydrase II
|
| gptkbp:MedlinePlusID |
a699058
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:molecularWeight |
383.51 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
B3 (Australia) |
| gptkbp:proteinBinding |
60%
|
| gptkbp:PubChem_CID |
54936
CHEMBL1201212 60977 DB01194 |
| gptkbp:routeOfAdministration |
ophthalmic
|
| gptkbp:RxNormID |
197964
|
| gptkbp:sideEffect |
blurred vision
bitter taste eye discomfort |
| gptkbp:UNII |
94502-02-6
|
| gptkbp:usedFor |
treatment of elevated intraocular pressure
treatment of ocular hypertension treatment of open-angle glaucoma |
| gptkbp:bfsParent |
gptkb:Carbonic_anhydrase_II
|
| gptkbp:bfsLayer |
7
|